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background:  Patients with acute coronary syndrome (ACS) who undergo percutaneous coronary intervention (PCI) but fail to respond to 
clopidogrel are at risk of recurrent ACS. Yet the majority of poor responders do not experience recurrent events. The highly cardio-specific 
biomarker, Heart-type Fatty Acid Binding Protein (H-FABP), may improve risk stratification
methods:  We studied a combined endpoint (death, definite/probable stent thrombosis and recurrent myocardial infarction) at 1 year in 758 
patients presenting with ACS without cardiogenic shock and undergoing PCI. Cardiac biomarkers measured at 0, 4 and 12 hours following 
PCI. A platelet function test (VerifyNow) was performed prior to PCI.
Results:  Clinical syndrome: 111 unstable angina; 536 non-STEMI; 111 STEMI. Mean age: 62 (12) years; female: 25%; median SYNTAX 
score: 8.0 (11.0). 28% IIbIIIa inhibitors. Clopidogrel hypo-response (PRU ≥ 238) found in 52.8%. H-FABP was elevated (≥ 2.0 µg/L) at 
baseline in 40%; of these, H-FABP was also elevated in 90% and 93% at 4 and 12 hours. Patients with both clopidogrel hypo-response 
and elevated baseline H-FABP (22.8%) had a higher rate of the endpoint at 1 year: adjusted hazard ratio (95% C.I.) 2.78 (1.34 to 5.69), p < 
0.01. Hypo-responders with normal H-FABP levels at baseline had a similar event rate to clopidogrel responders
conclusion:  Combining H-FABP and platelet function testing improves risk stratification in ACS patients undergoing PCI.
